FoxM1 insufficiency hyperactivates Ect2-RhoA-mDia1 signaling to drive cancer

Area of Science:

• Molecular biology
• Cancer research
• Cell biology

Background:

• Forkhead box M1 (FoxM1) is known to promote cell cycle progression and is often overexpressed in cancers, correlating with poor outcomes.
• Its precise role in tumor suppression and the underlying mechanisms remain incompletely understood.

Purpose of the Study:

• To investigate the role of FoxM1 as a tumor suppressor in mice.
• To elucidate the molecular mechanism by which FoxM1 inhibits tumorigenesis, focusing on its interaction with Ect2 and RhoA signaling.

Main Methods:

• Mouse models of tumorigenesis
• Biochemical assays to study protein interactions (FoxM1-Ect2)
• Analysis of cell cycle progression, centrosome movement, and mitotic spindle formation
• Correlation analysis of FOXM1 expression and RhoA GTPase activity in human cancers

Main Results:

• FoxM1 functions as a tumor suppressor in mice by inhibiting Ect2.
• FoxM1's N-terminal domain binds and inhibits Ect2, limiting RhoA GTPase and mDia1 activity.
• FoxM1 insufficiency leads to excessive cortical actin polymerization, impaired centrosome movement, and missegregation of chromosomes, driving tumorigenesis.
• Low FOXM1 expression correlates with RhoA GTPase hyperactivity in human cancers, validating the clinical relevance of this pathway.

Conclusions:

• FoxM1 suppresses tumors by inhibiting the Ect2-RhoA-mDia1 axis, thereby maintaining proper cell division.
• The findings reveal a novel tumor-suppressive function of FoxM1 and identify the Ect2-RhoA axis as a critical target for cancer therapy.